Allena Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with metabolic and kidney disorders. Co. is focused on metabolic disorders that result in excess accumulation of certain metabolites that stimulate inflammation, damage the kidney, and potentially lead to chronic kidney disease (CKD), and end-stage renal disease. Co.'s product candidate, ALLN-346, is an orally administered, urate degrading enzyme for patients with hyperuricemia and gout in the setting of improved CKD. Co. has conducted a Phase 1 program, including both a single-ascending dose and multiple-ascending dose study in healthy volunteers. The ALNA average annual return since 2017 is shown above.
The Average Annual Return on the ALNA average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ALNA average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALNA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|